Market Cap 1.27B
Revenue (ttm) 203.07M
Net Income (ttm) -54.84M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -27.01%
Debt to Equity Ratio -11.33
Volume 1,547,500
Avg Vol 2,548,452
Day's Range N/A - N/A
Shares Out 161.48M
Stochastic %K 51%
Beta 0.13
Analysts Strong Sell
Price Target $8.25

Company Profile

Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the...

Industry: Biotechnology
Sector: Healthcare
Phone: 844 445 5704
Address:
1375 West Fulton Street, Suite 1300, Chicago, United States
BuyThisOne
BuyThisOne Sep. 8 at 4:15 PM
$XERS if this channel holds for another 4-5 weeks I think we see $10+ after next earnings call.
0 · Reply
pascallambrecht
pascallambrecht Sep. 8 at 2:59 PM
$XERS september time action !!
0 · Reply
Bullisch_150
Bullisch_150 Sep. 8 at 1:00 PM
$XERS big deal or buyout after the corn
0 · Reply
Alon_R
Alon_R Sep. 8 at 12:12 PM
$XERS Sep 9 2025 | 10:00 AM EDT Fireside Chat at H.C. Wainwright Global Investment Conference ✔️ In the Sep. 3rd chat, Xeris shareholders were given several highly important updates: A)Xeris revenue continues to grow rapidly, and Mgmt. reaffirmed their impressive full-year growth guidance of 40–45%. This strongly suggests that Q3&Q4 are likely to be robust quarters B)They also reiterated their $750M revenue target for 2030. This likely reflects significant growth of Recorlev & impressive Gvoke growth. Combined with their outstanding gross margin of 82–85%,this sets Xeris apart as a company with a truly compelling growth and profitability profile C)Xeris expressed strong enthusiasm for XP-8121, the world’s only SQ levothyroxine option. This therapy addresses a critical unmet need for 20–40% patients who fail to achieve normalization,or sufficient control,with oral levo. This is a potential game-changer that could transform the lives of millions within this large patient population.
0 · Reply
Finwizard61
Finwizard61 Sep. 7 at 4:22 PM
$XERS We are now going to be unstoppable as already Cashflow positive and Recorlev going gangbusters!! No way we can remain below $10 for long. Smart money will come in and snap up the shares at this level. Also with chatter about takeover will further propel new investors & funds to acquire shares in Xeris. All in All Xeris is also a safe Place to invest $$$ in this turbulent market environment.. Urge all investors to join me to increase stake in Xeris..momentum on our side folks!! I see double figures in coming weeks….
0 · Reply
Finwizard61
Finwizard61 Sep. 7 at 1:35 PM
$XERS Only decision I have to make with respect to Xeris is whether or not to buy more shares now or after it cracks thru $8.00.. Either way I need another 20,000 shares in the next 12 months. Holding my mammoth holdings for the ultimate buyout be it 2 or 5 years. Matters not to me! Bullish beyond my imagination! Exit most likely North of $35.00! Waiting for my Porsche courage of Xeris!
1 · Reply
Bullisch_150
Bullisch_150 Sep. 7 at 10:43 AM
$XERS great deal XP-8121 in september?
0 · Reply
pascallambrecht
pascallambrecht Sep. 7 at 7:54 AM
$XERS 8 over next week no longer hold back old level 10/15 in the radar
0 · Reply
Ithaca2018
Ithaca2018 Sep. 7 at 3:49 AM
$XERS Our MVP plays his 1st game tomorrow night against the Buffalo Bills. 7:30 PM my time, not sure about yours. Can't wait, Go Ravens!
4 · Reply
NVDAMillionaire
NVDAMillionaire Sep. 5 at 9:55 PM
$XERS Great piece that accurately captures XERS's current position. So if you want to refresh your understanding of XERS or learn about XERS for the first time, this is essential reading. https://beyondspx.com/quote/XERS/xeris-biopharma-s-ascent-fueling-growth-with-differentiated-tech-and-expanding-markets-nasdaq-xers#analysis
0 · Reply
Latest News on XERS
Xeris In Recorlev-Fuelled Growth: Why I Choose To Buy

Sep 5, 2025, 10:03 AM EDT - 3 days ago

Xeris In Recorlev-Fuelled Growth: Why I Choose To Buy


Xeris Announces Details for Analyst & Investor Day

May 20, 2025, 7:30 AM EDT - 3 months ago

Xeris Announces Details for Analyst & Investor Day


Xeris Biopharma Holdings: Looking For More Growth In Q1 Earnings

May 7, 2025, 11:51 AM EDT - 4 months ago

Xeris Biopharma Holdings: Looking For More Growth In Q1 Earnings


Xeris Announces Changes to Its Board of Directors

Mar 28, 2025, 8:00 AM EDT - 5 months ago

Xeris Announces Changes to Its Board of Directors


Xeris Appoints Anh Nguyen, MD, MBA as Chief Medical Officer

Feb 24, 2025, 8:00 AM EST - 7 months ago

Xeris Appoints Anh Nguyen, MD, MBA as Chief Medical Officer


Xeris to Participate in Upcoming Investor Conferences

Feb 5, 2025, 8:00 AM EST - 7 months ago

Xeris to Participate in Upcoming Investor Conferences


Xeris Expects to Exceed Full-Year 2024 Financial Guidance

Jan 10, 2025, 7:00 AM EST - 8 months ago

Xeris Expects to Exceed Full-Year 2024 Financial Guidance


Xeris Biopharma Reports Third Quarter 2024 Financial Results

Nov 8, 2024, 7:00 AM EST - 10 months ago

Xeris Biopharma Reports Third Quarter 2024 Financial Results


Xeris Biopharma: Time For A Reassessment

Oct 9, 2024, 11:33 AM EDT - 11 months ago

Xeris Biopharma: Time For A Reassessment


Xeris Biopharma Announces CEO Succession Plan

Jul 8, 2024, 7:00 AM EDT - 1 year ago

Xeris Biopharma Announces CEO Succession Plan


Xeris Biopharma: Checking-In On One Of My 'Top Ideas'

Mar 30, 2024, 1:28 AM EDT - 1 year ago

Xeris Biopharma: Checking-In On One Of My 'Top Ideas'


Xeris Biopharma (XERS) Q4 2023 Earnings Call Transcript

Mar 6, 2024, 12:43 PM EST - 1 year ago

Xeris Biopharma (XERS) Q4 2023 Earnings Call Transcript


BuyThisOne
BuyThisOne Sep. 8 at 4:15 PM
$XERS if this channel holds for another 4-5 weeks I think we see $10+ after next earnings call.
0 · Reply
pascallambrecht
pascallambrecht Sep. 8 at 2:59 PM
$XERS september time action !!
0 · Reply
Bullisch_150
Bullisch_150 Sep. 8 at 1:00 PM
$XERS big deal or buyout after the corn
0 · Reply
Alon_R
Alon_R Sep. 8 at 12:12 PM
$XERS Sep 9 2025 | 10:00 AM EDT Fireside Chat at H.C. Wainwright Global Investment Conference ✔️ In the Sep. 3rd chat, Xeris shareholders were given several highly important updates: A)Xeris revenue continues to grow rapidly, and Mgmt. reaffirmed their impressive full-year growth guidance of 40–45%. This strongly suggests that Q3&Q4 are likely to be robust quarters B)They also reiterated their $750M revenue target for 2030. This likely reflects significant growth of Recorlev & impressive Gvoke growth. Combined with their outstanding gross margin of 82–85%,this sets Xeris apart as a company with a truly compelling growth and profitability profile C)Xeris expressed strong enthusiasm for XP-8121, the world’s only SQ levothyroxine option. This therapy addresses a critical unmet need for 20–40% patients who fail to achieve normalization,or sufficient control,with oral levo. This is a potential game-changer that could transform the lives of millions within this large patient population.
0 · Reply
Finwizard61
Finwizard61 Sep. 7 at 4:22 PM
$XERS We are now going to be unstoppable as already Cashflow positive and Recorlev going gangbusters!! No way we can remain below $10 for long. Smart money will come in and snap up the shares at this level. Also with chatter about takeover will further propel new investors & funds to acquire shares in Xeris. All in All Xeris is also a safe Place to invest $$$ in this turbulent market environment.. Urge all investors to join me to increase stake in Xeris..momentum on our side folks!! I see double figures in coming weeks….
0 · Reply
Finwizard61
Finwizard61 Sep. 7 at 1:35 PM
$XERS Only decision I have to make with respect to Xeris is whether or not to buy more shares now or after it cracks thru $8.00.. Either way I need another 20,000 shares in the next 12 months. Holding my mammoth holdings for the ultimate buyout be it 2 or 5 years. Matters not to me! Bullish beyond my imagination! Exit most likely North of $35.00! Waiting for my Porsche courage of Xeris!
1 · Reply
Bullisch_150
Bullisch_150 Sep. 7 at 10:43 AM
$XERS great deal XP-8121 in september?
0 · Reply
pascallambrecht
pascallambrecht Sep. 7 at 7:54 AM
$XERS 8 over next week no longer hold back old level 10/15 in the radar
0 · Reply
Ithaca2018
Ithaca2018 Sep. 7 at 3:49 AM
$XERS Our MVP plays his 1st game tomorrow night against the Buffalo Bills. 7:30 PM my time, not sure about yours. Can't wait, Go Ravens!
4 · Reply
NVDAMillionaire
NVDAMillionaire Sep. 5 at 9:55 PM
$XERS Great piece that accurately captures XERS's current position. So if you want to refresh your understanding of XERS or learn about XERS for the first time, this is essential reading. https://beyondspx.com/quote/XERS/xeris-biopharma-s-ascent-fueling-growth-with-differentiated-tech-and-expanding-markets-nasdaq-xers#analysis
0 · Reply
SparkyReturns
SparkyReturns Sep. 5 at 9:38 PM
$XERS Thanks, Paul. I give credit where credit is due. He was talking about Gvoke for gastro and insulin pumps 3-4 years ago when no one knew what the hell he was talking about. Then he was instrumental in making the Strongbridge deal, which I think was a win-win. And XP-8121 started under Paul. I believe in $40. Very grateful. Cheers! Enjoy the weekend!
4 · Reply
Alon_R
Alon_R Sep. 5 at 6:43 PM
$XERS When a company is growing rapidly in the short-to-mid term and has very strong growth levers for the long term, while already getting profitable and expanding its earnings, the picture becomes quite clear. If market participants require additional reassurance before driving the stock into a strong upward surge, they are likely to receive it in Q3 and Q4, just as they did in Q2. As management recently emphasized: A) There are no signs of Recorlev’s growth slowing down. B) They reaffirmed, just two days ago, their phenomenal overall growth outlook. What does this mean? It suggests that Xeris could see its **gross profit** soar to an impressive $340 million or more by next year. That would be enough to cover all company expenses, fully finance its double-to-triple blockbuster Phase 3 program, and still have a surplus left over. Truly, some remarkable times may lie ahead for this enterprise, short-to-mid-to-long term.
0 · Reply
jmalone13
jmalone13 Sep. 5 at 5:16 PM
$XERS what I like about the price action is that it dips then attempts a climb back up. 8 seems to be the resistance right now but it’s trending, good companies don’t always go strait up, it’s a nice looking chart here.
0 · Reply
cheetohottaki
cheetohottaki Sep. 5 at 3:30 PM
$XERS someone somehow absolutely doesn’t want this above $8, it’s quite astonishing how long we’ve lingered just below
3 · Reply
mendryl2
mendryl2 Sep. 5 at 3:30 PM
$XERS https://seekingalpha.com/article/4819956-xeris-in-recorlev-fuelled-growth-why-i-choose-to-buy
0 · Reply
PJACOB01
PJACOB01 Sep. 5 at 2:12 PM
$XERS XERS+PHAR could make a powerhouse for Rare Diseases Solutions. Unfortunately, the current political climate may not be suitable.
1 · Reply
Zabadora
Zabadora Sep. 5 at 2:01 PM
$XERS shorts are the downfall of the stock market
0 · Reply
biotech
biotech Sep. 5 at 1:57 PM
WE F*CKED $XERS SHORTS WE F*CKER $PGEN SHORTS WE WILL F*CK $SGMO SHORTS NEXT AND IT WILL BE THE GREATES SHORTF*CK EVER WITNESSED !!!!!
5 · Reply
Alon_R
Alon_R Sep. 5 at 6:19 AM
$XERS Xeris - Beta progress -> Highlight-> *By July 2025, Beta Bionics completed dosing for this trial. Preliminary pharmacodynamic data, were supportive of continued development of the glucagon candidate. Full results from the trial are expected in the second half of 2025 and will inform the go-forward development strategy for the glucagon candidate* The estimated FDA approval timeline for the Xeris-developed liquid-stable glucagon, intended for use in bihormonal iLet system, is approximately 2026–2027. This estimate is based on the completion of PK-PD bridging trials in H2 2025 and a potential NDA submission in late 25 or early 26. The FDA’s review takes ~ 10 months, 6 months under priority review, assuming no major safety concerns. The full bihormonal system, combining insulin and glucagon, may require additional approval as a combination product, likely extending the timeline to 2027–2028. These projections are approximate and depend on trial outcomes and regulatory review.
1 · Reply
BuyThisOne
BuyThisOne Sep. 5 at 12:09 AM
$XERS FYI, management specifically mentioned they consider the company profitable at this point and sustained moving forward as adjusted EBITDA being positive is their metric. The next 2 years should be interesting with trial costs and resultant EPS. Just gonna have to wait and see how it plays out. I think GAAP EPS and expected growth are the biggest drivers of stock price no matter what management thinks. If EPS is tempered due to trial costs the next 2 years it should explode in 2028 once they are done. The market is mostly efficient but it really mostly waits for published information to move. This is a great opportunity for individual investors to move first IMO. Just like it was from $1 to now. Many of us clearly saw what the future held and tried to tell everyone.
1 · Reply
ChartMill
ChartMill Sep. 4 at 10:54 PM
$XERS - Minervini Trend Template and VCP pattern. Narrow trading range
0 · Reply
BuyThisOne
BuyThisOne Sep. 4 at 8:10 PM
$XERS Who's gonna be right? Dave or Bear? Wagers anyone? I have 310k shares on Dave.
2 · Reply